Lushang Freda Pharmaceutical Co (SHSE:600223) PE Ratio without NRI: 30.84 (As of Aug. 07, 2026) — 13% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600223 Lushang Freda Pharmaceutical Co Ltd SHSE:600223
68 GF Score
Price ¥5.49
GF Value ¥6.56
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lushang Freda Pharmaceutical Co PE Ratio without NRI?

Lushang Freda Pharmaceutical Co SHSE:600223 68 PE Ratio without NRI is 30.84 as of Aug. 07, 2026, which is 13% above its 10-year median of 27.37. GuruFocus rates SHSE:600223 with a GF Score™ of 68/100 and a GF Value™ of ¥6.56 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,190 Real Estate companies, Lushang Freda Pharmaceutical Co ranks worse than 78.49% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-08-07), Lushang Freda Pharmaceutical Co's share price is ¥5.49. Lushang Freda Pharmaceutical Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.18. Therefore, Lushang Freda Pharmaceutical Co's PE Ratio without NRI for today is 30.84.

During the past 13 years, Lushang Freda Pharmaceutical Co's highest PE Ratio without NRI was 67.65. The lowest was 12.42. And the median was 27.37.

Lushang Freda Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2026 was ¥0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.18.

As of today (2026-08-07), Lushang Freda Pharmaceutical Co's share price is ¥5.49. Lushang Freda Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.16. Therefore, Lushang Freda Pharmaceutical Co's PE Ratio (TTM) for today is 34.31.

Good Sign:

Lushang Freda Pharmaceutical Co Ltd stock PE Ratio (=32.63) is close to 1-year low of 31.

During the past years, Lushang Freda Pharmaceutical Co's highest PE Ratio (TTM) was 406.00. The lowest was 13.52. And the median was 30.64.

Lushang Freda Pharmaceutical Co's EPS (Diluted) for the three months ended in Mar. 2026 was ¥0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.16.

Lushang Freda Pharmaceutical Co's EPS (Basic) for the three months ended in Mar. 2026 was ¥0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.16.


Lushang Freda Pharmaceutical Co  (SHSE:600223) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Lushang Freda Pharmaceutical Co PE Ratio without NRI Related Terms


Lushang Freda Pharmaceutical Co PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Lushang Freda Pharmaceutical Co's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lushang Freda Pharmaceutical Co PE Ratio without NRI Chart

Lushang Freda Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.86 176.50 68.79 36.00 43.29

Lushang Freda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.96 33.15 33.23 43.29 38.65

Lushang Freda Pharmaceutical Co PE Ratio without NRI Competitor Comparison

For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lushang Freda Pharmaceutical Co PE Ratio without NRI vs Real Estate Industry

For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Lushang Freda Pharmaceutical Co's PE Ratio without NRI falls into.


SHSE:600223
68GF Score
Lushang Freda Pharmaceutical Co Ltd SHSE:600223
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lushang Freda Pharmaceutical Co PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Lushang Freda Pharmaceutical Co's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=5.49/0.178
=30.84

Lushang Freda Pharmaceutical Co's Share Price of today is ¥5.49.
Lushang Freda Pharmaceutical Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 30.84 mean?
Lushang Freda Pharmaceutical Co (SHSE:600223) has a PE Ratio without NRI of 30.84 as of Aug. 07, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Lushang Freda Pharmaceutical Co and its competitors. This is 13% above median its historical median of 27.37. Over the past decade, Lushang Freda Pharmaceutical Co's PE Ratio without NRI has ranged from 12.42 to 67.65. According to the industry distribution chart, Lushang Freda Pharmaceutical Co ranks #934 out of 1190 companies in the Real Estate industry, placing it in the top 78.5%.
Is Lushang Freda Pharmaceutical Co's PE Ratio without NRI too high?
Lushang Freda Pharmaceutical Co's current PE Ratio without NRI of 30.84 is 13% above median its 10-year median of 27.37. Over the past 10 years, this metric has ranged from a low of 12.42 to a high of 67.65. The Real Estate industry median PE Ratio without NRI is 12.95. Lushang Freda Pharmaceutical Co's value of 30.84 is 138.2% above this industry median. Based on the distribution chart, Lushang Freda Pharmaceutical Co ranks #934 out of 1190 companies in the Real Estate industry, which is in the bottom quartile relative to peers. Overall, Lushang Freda Pharmaceutical Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lushang Freda Pharmaceutical Co's PE Ratio without NRI compare to competitors?
According to the Real Estate industry distribution chart, Lushang Freda Pharmaceutical Co ranks #934 out of 1190 companies for PE Ratio without NRI. This places Lushang Freda Pharmaceutical Co in the lower half of its industry. The industry median PE Ratio without NRI is 12.95. Lushang Freda Pharmaceutical Co's value of 30.84 is 138.2% above this benchmark. Historically, Lushang Freda Pharmaceutical Co's own PE Ratio without NRI has ranged from 12.42 to 67.65 over the past decade. While the company's 10-year median is 27.37 vs. the industry median of 12.95, Lushang Freda Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Real Estate company?
The median PE Ratio without NRI among Real Estate companies is 12.95, based on 1,190 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lushang Freda Pharmaceutical Co's current PE Ratio without NRI of 30.84 is 138.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Lushang Freda Pharmaceutical Co and its competitors. For the Real Estate industry, the median PE Ratio without NRI is 12.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lushang Freda Pharmaceutical Co's current PE Ratio without NRI is 30.84, which is 13% above median its own 10-year median of 27.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lushang Freda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co (SHSE:600223) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥6.56, compared to a current price of ¥5.49 — trading 16.3% below its estimated fair value. The current PE Ratio without NRI is 30.84, which is 13% above median its 10-year median of 27.37 and 138.2% above the Real Estate industry median of 12.95. Lushang Freda Pharmaceutical Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Lushang Freda Pharmaceutical Co (SHSE:600223), the current PE Ratio without NRI is 30.84 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lushang Freda Pharmaceutical Co (SHSE:600223) Overvalued in 2026?

Based on GuruFocus' analysis, Lushang Freda Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥5.49 is trading 16.3% below its estimated GF Value™ of ¥6.56. GuruFocus considers Lushang Freda Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600223:

  • PE Ratio without NRI: 30.84 (13% above median its 10-year median of 27.37)
  • GF Value™: ¥6.56 vs. price of ¥5.49 (16.3% below fair value)
  • GF Score™: 68/100 with 2 warning signs
  • Industry Position: 138.2% above the Real Estate median (#934 of 1190)

No single metric tells the full story. See the SHSE:600223 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lushang Freda Pharmaceutical Co Business Description

Address No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
68GF Score

Get the complete analysis for SHSE:600223

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.49
Price
¥6.56
GF Value